ClinVar Miner

Submissions for variant NM_000492.4(CFTR):c.4333G>A (p.Asp1445Asn) (rs148783445)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 11
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Invitae RCV000047128 SCV000075141 likely benign Cystic fibrosis 2020-11-23 criteria provided, single submitter clinical testing
Quest Diagnostics Nichols Institute San Juan Capistrano RCV000506986 SCV000601121 uncertain significance not specified 2017-06-05 criteria provided, single submitter clinical testing
Women's Health and Genetics/Laboratory Corporation of America, LabCorp RCV000506986 SCV000697023 uncertain significance not specified 2021-04-11 criteria provided, single submitter clinical testing Variant summary: CFTR c.4333G>A (p.Asp1445Asn) results in a conservative amino acid change in the encoded protein sequence. Four of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 0.00034 in 251444 control chromosomes, predominantly at a frequency of 0.002 within the African or African-American subpopulation in the gnomAD database. This frequency is lower than the estimated maximum frequency expected for a pathogenic variant in CFTR causing Cystic Fibrosis (0.002 vs 0.013) allowing no conclusion about variant significance. c.4333G>A has been reported in the literature in individuals affected with or suspected to exhibit symptoms of Cystic Fibrosis and Cystic Fibrosis related disorders (examples- Claustres_2000, Schrijver_2005, Trujilliano_2015, Zeigler_2020). These reports do not provide unequivocal conclusions about association of the variant with Cystic Fibrosis. The variant has also been reported in compound heterozygosity with a well-known pathogenic mutation (CFTR F508del) in at least one infant who had a normal sweat chloride test (Castellani_2016). In addition, the variant has been reported in individuals affected with pancreatitis (Keiles_2006, Masson_2013), sarcoidosis (Makrythanasis_2010), and congenital unilateral absence of vas deferens (CUAVD; Mieusset_2019), but without strong evidence for causality. At least one publication reports experimental evidence indicating that the variant does not disrupt interactions with AMPK in a yeast-based assay (Hallows_2000), however the clinical significance of this finding is not clear. Nine other clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation, citing the variant as uncertain significance (n=8) and likely benign (n=1). Based on the evidence outlined above, the variant was classified as uncertain significance.
EGL Genetic Diagnostics, Eurofins Clinical Diagnostics RCV000586730 SCV000700517 uncertain significance not provided 2018-04-27 criteria provided, single submitter clinical testing
ARUP Laboratories, Molecular Genetics and Genomics,ARUP Laboratories RCV001283444 SCV000885178 uncertain significance none provided 2020-08-20 criteria provided, single submitter clinical testing The CFTR c.4333G>A; p.Asp1445Asn variant (rs148783445) is reported in the medical literature in individuals affected with cystic fibrosis or other CFTR-related disorders (Castellani 2017, Claustres 2000, Keiles 2006, Masson 2013, Picca 2010, Schrijver 2005). This variant is reported in ClinVar (Variation ID: 53941), and is found in the general population with an overall allele frequency of 0.04% (106/282286 alleles) in the Genome Aggregation Database. The aspartic acid at codon 1445 is weakly conserved, but computational analyses (SIFT, PolyPhen-2) predict that this variant is deleterious. However, given the lack of specific clinical and functional data, the significance of the p.Asp1445Asn variant is uncertain at this time. References: Castellani C et al. Sweat chloride and immunoreactive trypsinogen in infants carrying two CFTR mutations and not affected by cystic fibrosis. Arch Dis Child. 2017 Jul;102(7):644-646. Claustres M et al. Spectrum of CFTR mutations in cystic fibrosis and in congenital absence of the vas deferens in France. Hum Mutat. 2000;16(2):143-56. Keiles S et al. Identification of CFTR, PRSS1, and SPINK1 mutations in 381 patients with pancreatitis. Pancreas. 2006 Oct;33(3):221-7. Masson E et al. A Conservative Assessment of the Major Genetic Causes of Idiopathic Chronic Pancreatitis: Data from a Comprehensive Analysis of PRSS1, SPINK1, CTRC and CFTR Genes in 253 Young French Patients. PLoS One. 2013; 8(8): e73522. Picci L et al. A 10-year large-scale cystic fibrosis carrier screening in the Italian population. J Cyst Fibros. 2010 Jan;9(1):29-35. Schrijver I et al. Diagnostic Testing by CFTR Gene Mutation Analysis in a Large Group of Hispanics. J Mol Diagn. 2005 May; 7(2): 289–299.
Mendelics RCV000047128 SCV000886359 uncertain significance Cystic fibrosis 2018-11-05 criteria provided, single submitter clinical testing
CeGaT Praxis fuer Humangenetik Tuebingen RCV000586730 SCV001155244 uncertain significance not provided 2016-08-01 criteria provided, single submitter clinical testing
Johns Hopkins Genomics, Johns Hopkins University RCV000047128 SCV001167307 uncertain significance Cystic fibrosis 2019-11-22 criteria provided, single submitter clinical testing This CFTR variant has been previously identified in patients with features of cystic fibrosis, but also in one infant with a normal sweat chloride concentration. The clinical significance of this variant is classified as uncertain by multiple submitters in ClinVar. CFTR c.4333G>A (rs148783445) has been identified in a large population datasets and the minor allele frequency is neither low enough to consider the variant rare (<0.1%) nor high enough to consider it a population polymorphism (>1%) within the African subpopulation (gnomAD: 50/24958 alleles; 0.02%, no homozygotes). Of three bioinformatics tools queried, two predict that the substitution would be possibly damaging, while one predicts that it would be tolerated. The aspartic acid residue at this position is conserved across many, but not all of the species assessed. We consider the clinical significance of c.4333G>A to be uncertain at this time.
Ambry Genetics RCV001022311 SCV001184030 uncertain significance Inborn genetic diseases 2020-10-13 criteria provided, single submitter clinical testing The p.D1445N variant (also known as c.4333G>A), located in coding exon 27 of the CFTR gene, results from a G to A substitution at nucleotide position 4333. The aspartic acid at codon 1445 is replaced by asparagine, an amino acid with highly similar properties. This variant was reported in individuals with cystic fibrosis; however, specific phenotype and genotype information were not provided (Schrijver I et al. J Mol Diagn, 2005 May;7:289-99; Zeiger AM et al. Pediatr Pulmonol, 2020 02;55:533-540). In an individual with an abnormal newborn screen, this variant was detected in conjunction with p.F508del (phase unknown) with a sweat chloride level of 20 mmol/L (Castellani C et al. Arch Dis Child, 2017 07;102:644-646). This variant was detected in an individual with idiopathic chronic pancreatitis with a second CFTR variant; phase information was not provided (Masson E et al. PLoS One, 2013 Aug;8:e73522). In one study, p.D1445N had no effect on the interaction strength between the CFTR COOH-terminal tail and AMP-activated protein kinase and did not appear important for binding (Hallows KR et al. J. Clin. Invest., 2000 Jun;105:1711-21). This amino acid position is not well conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear.
Clinical Genetics Karolinska University Hospital,Karolinska University Hospital RCV000586730 SCV001450106 likely pathogenic not provided 2014-07-29 criteria provided, single submitter clinical testing
Natera, Inc. RCV000047128 SCV001460123 uncertain significance Cystic fibrosis 2017-05-17 no assertion criteria provided clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.